Virtu Financial’s Capricor Therapeutics CAPR Stock Holding History

Virtu Financial’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,058	Closed	-$215K	–	1652
2026 Q1	$215K	Buy	+7,058	New	+$188K	0.01%	992
2024 Q4	–	Sell	-30,112	Closed	-$458K	–	1584
2024 Q3	$458K	Buy	+30,112	New	+$149K	0.03%	488
2023 Q2	–	Sell	-16,895	Closed	-$71K	–	1549
2023 Q1	$71K	Buy	+16,895	New	+$72.7K	0.01%	1043
2021 Q4	–	Sell	-55,200	Closed	-$222K	–	1742
2021 Q3	$222K	Buy	+55,200	New	+$251K	0.02%	869
2020 Q3	–	Sell	-57,444	Closed	-$264K	–	1099
2020 Q2	$264K	Buy	+57,444	New	+$250K	0.03%	610
2019 Q1	–	Sell	-2,025	Closed	-$8K	–	1440
2018 Q4	$8K	Buy	2,025 +913	+82%	+$7.25K	﹤0.01%	1457
2018 Q3	$12K	Sell	1,112 -4,564	-80%	-$54.4K	﹤0.01%	1438
2018 Q2	$76K	Buy	5,676 +435	+8%	+$5.92K	﹤0.01%	1698
2018 Q1	$71K	Buy	+5,241	New	+$90.9K	﹤0.01%	1645

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Virtu Financial's CAPR Position: Q2 2026 in Review

Virtu Financial sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 7,058 shares — an estimated $215K sold.

Virtu Financial first reported a position in CAPR in Q1 2018 and held it in 9 quarters. The position peaked at $458K in Q3 2024. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Virtu Financial reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 7,058 Capricor Therapeutics shares in Q2 2026, an estimated $215K.
Virtu Financial first reported a position in Capricor Therapeutics in Q1 2018 and held it in 9 quarters.
Virtu Financial's Capricor Therapeutics position peaked at $458K in Q3 2024.
170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.